In Vivo's Deals Of The Month, October 2017

In Vivo's editors pick October's most significant deals, including bold moves from Vir Biotechnology and the birth of a major generics player. (Free article.)

IV_DOTM_1200

Vir Biotechnology Inc. launched just 11 months ago, but has already amassed a $500 million war chest to battle infectious disease. It spent some of the money this month on potential billion-dollar strategic alliances with Visterra Inc. (development of up to six antibodies derived from Visterra's Hierotope platform) and Alnylam Pharmaceuticals Inc.(evaluation of up to five RNAi therapeutics.) [See Deal][See Deal] Also in October, Vir forged research agreements with Harvard University, Oregon Health & Science University and Fred Hutchinson Cancer Research Center,licensed technology from Stanford University, and acquired Swiss biotech Humabs BioMed SA for good measure.

CNS rare disease specialist Harmony Biosciences LLC raised $270 million in early-stage equity financing and will use part of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

More from In Vivo

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By 

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By 

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy